Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology

Search Medical Condition
Please enter condition
Please choose location
 

Hemoglobinuria, Paroxysmal Clinical Trials

A listing of Hemoglobinuria, Paroxysmal medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

Proof of Concept Study to Assess the Efficacy Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

To determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with PNH.

Phase

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Coversin, a small protein complement C5 inhibitor which prevents the cleavage of C5 by C5 convertase into C5a and C5b, will be used in an open label, non-comparative clinical trial in patients with PNH and proven resistance to eculizumab due to C5 polymorphisms. Patients will be treated with Coversin by ...

Phase

ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Na ve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The purpose of this study is to assess ALXN1210 compared to eculizumab in adult patients with PNH who have not previously used a complement inhibitor.

Phase

Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.

Phase

A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The purpose of this study is to determine the safety and effectiveness of ACH-0144471 in currently untreated patients with PNH. This study is designed to include 4 to 12 patients.

Phase

Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will ...

Phase

Study to Assess Safety Efficacy Pharmacokinetics and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

This is a Phase I/II, first-in-human study consisting of 3 sequential parts in which the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single-doses of RO7112689 will be evaluated in healthy volunteers (HV) during Part I, and safety, tolerability, PK, PD, and efficacy of multiple-doses of RO7112689 will be evaluated ...

Phase

Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study

The purpose of this study is to enable continued access to RA101495 for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a RA101495 clinical study.

Phase